Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Gulo who wrote (6201)	4/22/2002 2:33:31 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

ONXX Part of the recent move may have been on a TA basis.<g> Message 17300084 There were recent reports at the (AACR) meeting in San Francisco. Researchers presented data based on seven abstracts covering Onyx's novel therapeutic virus products, including ONYX-015 clinical data in patients with sarcoma and patients with liver metastases of colorectal cancer. biz.yahoo.com Dow Jones also reported on April 8 that ONYX-015 seems to slow tumor growth. Ladenburg Thalmann & Co. Inc. had a 3 pages report on 4/10/2002: Onyx Pharmaceuticals, Inc.: SUPPORTING DATA FOR ONCOLYTIC VIRUS AND BAY 43-9006 PROGRAMS AT AACR Onyx Pharmaceuticals, Inc.: EMPHASIS SHIFT: DELAYING ONYX-015, ACCELERATING BAY 43-9006 From a TA standpoint, after it went through the resistance at 5.50 on April 8 it was not able to meet the heavy overhead resistance from the 9.10 to 12 level from last Summer It faltered at the 8.98 level on Thursday. The support now stands at 7.20 and then 6.50 <g> Bernard